• Galectin Therapeutics Inc., of Norcross, Ga., said five of the eight patients have been enrolled and infused in the first cohort of its blinded Phase 1 trial of GR-MD-02 for patients with nonalcoholic steatohepatitis (NASH or fatty liver disease) with advanced fibrosis.